摘要
目的:了解非小细胞肺癌患者术后辅助化疗的用药情况。方法:采用病例回顾分析方法,对某院2012年接受术后化疗的非小细胞肺癌患者的药物治疗方案、药物利用情况和药物不良反应进行统计分析。结果:156例患者共使用了8种化疗方案,使用例次最多的是NC(长春瑞滨+卡铂)方案,药物费用最高的是PC(培美曲塞+卡铂)方案。化疗辅助用药中药物利用指数排名前列的是质子泵抑制药、重组人促红细胞生成素、香菇多糖。结论:非小细胞肺癌患者术后化疗方案的选择及辅助用药的选用仍需进一步规范,临床外科医师应与药师密切配合,参与治疗过程的监测,促进合理用药。
Objective： To explore the drug application in the postoperative chemotherapy for the patients with non small cell lung cancer. Methods： The chemotherapy regimens, drug utilization and adverse drug reactions in the non- small cell lung cancer patients received postoperative chemotherapy in 2012 were statistically analyzed in a retrospective study. Results：Totally 8 kinds of chemotherapy regimens were used in 156 cases. The NC（vinorelbine ＋ carboplatin） regimen was used most frequently and the PC（pemetrexed ＋ carboplatin） regimen was with the highest expense. Proton pump inhibitors, recombinant human erythropoietin and lentinan were the top three in the adjuvant drugs used in the treatment. Conclusion： It is necessary to further standardize the postoperative chemotherapy for non small cell lung cancer patients. Thoracic surgeons along with pharmacists should strengthen the drug use monitoring during the whole treatment process to promote the rational drug use.
出处
《中国药师》
CAS
2014年第2期293-295,共3页
China Pharmacist
关键词
非小细胞肺癌
术后化疗
用药分析
药物利用
Non-small cell lung cancer
Postoperative chemotherapy
Analysis of drug use
Drug utilization
